Source
Department of Dermatology, INSERM U601, CHU Hôtel-Dieu, Nantes, France.
Abstract
BACKGROUND:
Hidradenitis suppurativa (Verneuil's disease) is a chronic suppurative dermatosis involving apocrine glands with a severe impact on the quality of life, which is enhanced by the fact that the drugs usually prescribed are poorly effective.
OBJECTIVE:
We discuss a new therapeutic approach based on zinc salts.
METHODS:
We performed a pilot study on 22 patients, mainly from grade I or II in Hurley's classification. All included patients had previously been prescribed a treatment (antibiotic, isotretinoin, surgery or anti-androgens), which was inefficient. They were then treated with 90 mg of zinc gluconate per day (15 mg zinc per Rubozinc capsule).
RESULTS:
We observed a clinical response in all patients, with 8 complete remissions (CR) and 14 partial remissions (PR). When CR was obtained, the treatment was progressively decreased (average of 3.5 capsules/day); 4/22 patients experienced side-effects, mainly gastro-intestinal.
CONCLUSION:
Zinc salts could provide a new therapeutic alternative for the treatment of hidradenitis suppurativa.
2007 S. Karger AG, Basel